Avadel Pharma secures exclusive rights to nocturia candidate Noctiva in U.S. and Canada [Seeking Alpha]
Avadel Pharmaceuticals plc - Ordinary Share (AVDL)
Last avadel pharmaceuticals plc - ordinary share earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
avadel.com
Company Research
Source: Seeking Alpha
Avadel Pharmaceuticals (NASDAQ: AVDL ) inks an agreement with privately held Serenity Pharmaceuticals securing exclusive development and commercialization rights to Noctiva, a low-dose formulation of desmopressin delivered intranasally, for the treatment of nocturnal polyuria (excessive urination at night) in the U.S. and Canada. Under the terms of the agreement, Avadel will pay Serenity $50M upfront, $20M at full-scale commercial launch or June 30, 2018, performance-based milestones and tiered royalties. The FDA approved Noctiva in March. Avadel will host a conference call tomorrow, Wednesday, September 6 at 8:30 am ET to discuss the transaction. Previously: Avadel Pharma in talks with Serenity Pharma for nocturia med Noctiva (Aug. 17) Now read: Valeant Pharmaceuticals: Due For A Rebound »
Show less
Read more
Impact Snapshot
Event Time:
AVDL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVDL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVDL alerts
High impacting Avadel Pharmaceuticals plc - Ordinary Share news events
Weekly update
A roundup of the hottest topics
AVDL
News
- Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8GlobeNewswire
- Avadel Pharmaceuticals plc (NASDAQ:AVDL) Is Expected To Breakeven In The Near Future [Yahoo! Finance]Yahoo! Finance
- Avadel Pharmaceuticals plc (NASDAQ: AVDL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.MarketBeat
- Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution [Seeking Alpha]Seeking Alpha
- Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference [Yahoo! Finance]Yahoo! Finance
AVDL
Earnings
- 11/8/23 - Miss
AVDL
Sec Filings
- 5/3/24 - Form 3
- 4/26/24 - Form 10-K/A
- 4/15/24 - Form 8-A12B
- AVDL's page on the SEC website